The Mulligan Lab at Wake Forest University was working on a dose response study of the Hsp70 protein with the hopes that their ALS scientists and clinicians would be able to start to design initial clinical trials in patients. Unexpectedly, the protein does not prevent neuromuscular junction denervation in the mouse model of ALS.
